Investors with the goal of beating the broader market often turn to stock selection. Strategic choices in individual stocks can have a profound impact on your wealth.
After finishing at $3.01 in the prior trading day, Akebia Therapeutics Inc (NASDAQ: AKBA) closed at $3.13, up 3.99%. In other words, the price has increased by $3.99 from its previous closing price. On the day, 3.1 million shares were traded. AKBA stock price reached its highest trading level at $3.15 during the session, while it also had its lowest trading level at $3.01.
Ratios:
Our goal is to gain a better understanding of AKBA by taking a closer look at its different ratios. For the most recent quarter (mrq), Quick Ratio is recorded 1.84 and its Current Ratio is at 1.98. In the meantime, Its Debt-to-Equity ratio is 7.21 whereas as Long-Term Debt/Eq ratio is at 6.10.
On April 28, 2025, Leerink Partners started tracking the stock assigning a Outperform rating and target price of $7.
On April 01, 2025, Jefferies started tracking the stock assigning a Buy rating and target price of $6.Jefferies initiated its Buy rating on April 01, 2025, with a $6 target price.
Insider Transactions:
The insider trade also gives investors a glimpse into the future direction of stock prices, which can be beneficial to investors. A recent insider transaction in this stock occurred on Jun 30 ’25 when Ostrowski Erik sold 41,314 shares for $3.67 per share. The transaction valued at 151,622 led to the insider holds 503,586 shares of the business.
Ostrowski Erik bought 41,314 shares of AKBA for $151,622 on Jun 30 ’25. On Jun 09 ’25, another insider, Malabre Richard C, who serves as the SVP, Chief Accounting Officer of the company, sold 15,000 shares for $4.01 each. As a result, the insider received 60,150 and left with 266,914 shares of the company.
Valuation Measures:
Investors should consider key stock statistics when deciding whether to invest or divest. In the wake of the recent closing price, AKBA now has a Market Capitalization of 829903872 and an Enterprise Value of 856675584. For the stock, the TTM Price-to-Sale (P/S) ratio is 4.07 while its Price-to-Book (P/B) ratio in mrq is 28.17. Its current Enterprise Value per Revenue stands at 4.205 whereas that against EBITDA is 36.692.
Stock Price History:
The Beta on a monthly basis for AKBA is 1.02, which has changed by 0.9802631 over the last 52 weeks, in comparison to a change of 0.15109766 over the same period for the S&P500. Over the past 52 weeks, AKBA has reached a high of $4.08, while it has fallen to a 52-week low of $1.24. The 50-Day Moving Average of the stock is -12.17%, while the 200-Day Moving Average is calculated to be 22.57%.
Shares Statistics:
The stock has traded on average 4.69M shares per day over the past 3-months and 3953730 shares per day over the last 10 days, according to various share statistics. A total of 263.04M shares are outstanding, with a floating share count of 250.51M. Insiders hold about 5.52% of the company’s shares, while institutions hold 39.95% stake in the company. Shares short for AKBA as of 1755216000 were 24814352 with a Short Ratio of 5.29, compared to 1752537600 on 25373233. Therefore, it implies a Short% of Shares Outstanding of 24814352 and a Short% of Float of 9.46.
Earnings Estimates
The current assessment of Akebia Therapeutics Inc (AKBA) involves the perspectives of 2.0 analysts closely monitoring its market dynamics.The consensus estimate for the next quarter is -$0.03, with high estimates of -$0.02 and low estimates of -$0.04.
Analysts are recommending an EPS of between -$0.02 and -$0.04 for the fiscal current year, implying an average EPS of -$0.03. EPS for the following year is $0.26, with 2.0 analysts recommending between $0.41 and $0.11.
Revenue Estimates
5 analysts predict $52.06M in revenue for the current quarter. It ranges from a high estimate of $65.5M to a low estimate of $45.54M. As of the current estimate, Akebia Therapeutics Inc’s year-ago sales were $37.43MFor the next quarter, 5 analysts are estimating revenue of $54.1M. There is a high estimate of $76.4M for the next quarter, whereas the lowest estimate is $38.85M.
A total of 5 analysts have provided revenue estimates for AKBA’s current fiscal year. The highest revenue estimate was $261.7M, while the lowest revenue estimate was $204.2M, resulting in an average revenue estimate of $226M. In the same quarter a year ago, actual revenue was $160.18MBased on 5 analysts’ estimates, the company’s revenue will be $298.52M in the next fiscal year. The high estimate is $396.3M and the low estimate is $227.9M.
